
Browsing restrictions can be lifted for a fee.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell and treatments in Taiwan. It provides outsourced production services; commissioned development and manufacturing services for various cells and cell derivatives; commissioned inspection; advisory; laboratory information management system; and sterile filling services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
6986
和迅
-3.80%
(-0.04)
The most recent financial report for 和迅 (6986) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6986's short-term business performance and financial health. For the latest updates on 6986's earnings releases, visit this page regularly.
According to historical valuation range analysis, 和迅 (6986)'s current price-to-earnings (P/E) ratio is 22.41, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 和迅 (6986) reported an Operating Profit of 12.2M with an Operating Margin of 21.57% this period, representing a decline of 67.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 和迅 (6986) announced revenue of 56.56M, with a Year-Over-Year growth rate of -19.41%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 和迅 (6986) held Total Cash and Cash Equivalents of 264.9M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 和迅 (6986) achieved the “three margins increasing” benchmark, with a gross margin of 86.09%%, operating margin of 21.57%%, and net margin of 23.99%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6986's profit trajectory and future growth potential.
According to the past four quarterly reports, 和迅 (6986)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.29. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.